Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnnabel Samimy - Managing DirectorJoe Pantginis - Managing DirectorJoohwan Kim - Assistant VP of BiotechnologyLauren Hay - VP of Strategic Planning and Investment AnalyticsMelanie Herman - Executive Director of Investor RelationsTavo Espinoza - CFOTodd Davis - CEOConference Call ParticipantsJohn Vandermosten - Senior AnalystMatt Hewitt - Senior Research AnalystPete Lucas - AnalystTrevor Allred - Ex ...

Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAnnabel Samimy - Managing DirectorJoe Pantginis - Managing DirectorJoohwan Kim - Assistant VP of BiotechnologyLauren Hay - VP of Strategic Planning and Investment AnalyticsMelanie Herman - Executive Director of Investor RelationsTavo Espinoza - CFOTodd Davis - CEOConference Call ParticipantsJohn Vandermosten - Senior AnalystMatt Hewitt - Senior Research AnalystPete Lucas - AnalystTrevor Allred - Ex ...

Ligand Pharmaceuticals (NasdaqGM:LGND) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker7Thank you for standing by, and welcome to Ligand's fourth quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by 1 on your telephone keypad. If you would like to withdraw your question, please press star one again. ...